India’s Ranbaxy Denies Orchid Hostile Takeover Bid
This article was originally published in PharmAsia News
Responding to a rash of speculation it plans to acquire Orchid Chemicals, Ranbaxy Laboratories denied the firm plans an all-India hostile takeover. Ranbaxy CEO Malvinder Singh issued the denial, but declined to comment on his firm's relationship with Solrex Pharmaceuticals, which recently increased its stake in Orchid to nearly 12 percent. There has been speculation Solrex is part of the Ranbaxy Group and neither firm is considered likely to be willing to buy 12 percent of another company just to be its financial adviser. Singh's statements suggest Ranbaxy plans to negotiate an amicable takeover. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.